| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Standard atomic weight Ar°(Ga) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Natural gallium (31Ga) consists of a mixture of two stable isotopes: gallium-69 and gallium-71. Synthetic radioisotopes are known with atomic masses ranging from 60 to 89, along with seven nuclear isomers. Most of the isotopes with atomic mass numbers below 69 decay by electron capture and positron emission to isotopes of zinc, while most of the isotopes with masses above 71 beta decay to isotopes of germanium.
The medically important radioisotopes are gallium-67 and gallium-68, used for imaging, and further described below.
List of isotopes
[edit]
Nuclide [n 1] |
Z | N | Isotopic mass (Da)[4] [n 2][n 3] |
Half-life[1] |
Decay mode[1] [n 4] |
Daughter isotope [n 5] |
Spin and parity[1] [n 6][n 7] |
Natural abundance (mole fraction) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Excitation energy | Normal proportion[1] | Range of variation | |||||||||||||||||
59Ga | 31 | 28 | |||||||||||||||||
60Ga | 31 | 29 | 59.95750(22)# | 72.4(17) ms | β+ (98.4%) | 60Zn | (2+) | ||||||||||||
β+, p (1.6%) | 59Cu | ||||||||||||||||||
β+, α? (<0.023%) | 56Ni | ||||||||||||||||||
61Ga | 31 | 30 | 60.949399(41) | 165.9(25) ms | β+ | 61Zn | 3/2− | ||||||||||||
β+, p? (<0.25%) | 60Cu | ||||||||||||||||||
62Ga | 31 | 31 | 61.94418964(68) | 116.122(21) ms | β+ | 62Zn | 0+ | ||||||||||||
63Ga | 31 | 32 | 62.9392942(14) | 32.4(5) s | β+ | 63Zn | 3/2− | ||||||||||||
64Ga | 31 | 33 | 63.9368404(15) | 2.627(12) min | β+ | 64Zn | 0(+#) | ||||||||||||
64mGa | 42.85(8) keV | 21.9(7) μs | IT | 64Ga | (2+) | ||||||||||||||
65Ga | 31 | 34 | 64.93273442(85) | 15.133(28) min | β+ | 65Zn | 3/2− | ||||||||||||
66Ga | 31 | 35 | 65.9315898(12) | 9.304(8) h | β+ | 66Zn | 0+ | ||||||||||||
67Ga[n 8] | 31 | 36 | 66.9282023(13) | 3.2617(4) d | EC | 67Zn | 3/2− | ||||||||||||
68Ga[n 8] | 31 | 37 | 67.9279802(15) | 67.842(16) min | β+ | 68Zn | 1+ | ||||||||||||
69Ga | 31 | 38 | 68.9255735(13) | Stable | 3/2− | 0.60108(50) | |||||||||||||
70Ga | 31 | 39 | 69.9260219(13) | 21.14(5) min | β− (99.59%) | 70Ge | 1+ | ||||||||||||
EC (0.41%) | 70Zn | ||||||||||||||||||
71Ga | 31 | 40 | 70.92470255(87) | Stable | 3/2− | 0.39892(50) | |||||||||||||
72Ga | 31 | 41 | 71.92636745(88) | 14.025(10) h | β− | 72Ge | 3− | ||||||||||||
72mGa | 119.66(5) keV | 39.68(13) ms | IT | 72Ga | (0+) | ||||||||||||||
73Ga | 31 | 42 | 72.9251747(18) | 4.86(3) h | β− | 73Ge | 1/2− | ||||||||||||
73mGa | 0.15(9) keV | <200 ms | IT? | 73Ga | 3/2− | ||||||||||||||
β− | 73Ge | ||||||||||||||||||
74Ga | 31 | 43 | 73.9269457(32) | 8.12(12) min | β− | 74Ge | (3−) | ||||||||||||
74mGa | 59.571(14) keV | 9.5(10) s | IT (>75%) | 74Ga | (0)(+#) | ||||||||||||||
β−? (<25%) | 74Ge | ||||||||||||||||||
75Ga | 31 | 44 | 74.92650448(72) | 126(2) s | β− | 75Ge | 3/2− | ||||||||||||
76Ga | 31 | 45 | 75.9288276(21) | 30.6(6) s | β− | 76Ge | 2− | ||||||||||||
77Ga | 31 | 46 | 76.9291543(26) | 13.2(2) s | β− | 77mGe (88%) | 3/2− | ||||||||||||
77Ge (12%) | |||||||||||||||||||
78Ga | 31 | 47 | 77.9316109(11) | 5.09(5) s | β− | 78Ge | 2− | ||||||||||||
78mGa | 498.9(5) keV | 110(3) ns | IT | 78Ga | |||||||||||||||
79Ga | 31 | 48 | 78.9328516(13) | 2.848(3) s | β− (99.911%) | 79Ge | 3/2− | ||||||||||||
β−, n (0.089%) | 78Ge | ||||||||||||||||||
80Ga | 31 | 49 | 79.9364208(31) | 1.9(1) s | β− (99.14%) | 80Ge | 6− | ||||||||||||
β−, n (.86%) | 79Ge | ||||||||||||||||||
80mGa[n 9] | 22.45(10) keV | 1.3(2) s | β− | 80Ge | 3− | ||||||||||||||
β−, n? | 79Ge | ||||||||||||||||||
IT | 80Ga | ||||||||||||||||||
81Ga | 31 | 50 | 80.9381338(35) | 1.217(5) s | β− (87.5%) | 81mGe | 5/2− | ||||||||||||
β−, n (12.5%) | 80Ge | ||||||||||||||||||
82Ga | 31 | 51 | 81.9431765(26) | 600(2) ms | β− (78.8%) | 82Ge | 2− | ||||||||||||
β−, n (21.2%) | 81Ge | ||||||||||||||||||
β−, 2n? | 80Ge | ||||||||||||||||||
82mGa | 140.7(3) keV | 93.5(67) ns | IT | 82Ga | (4−) | ||||||||||||||
83Ga | 31 | 52 | 82.9471203(28) | 310.0(7) ms | β−, n (85%) | 82Ge | 5/2−# | ||||||||||||
β− (15%) | 83Ge | ||||||||||||||||||
β−, 2n? | 81Ge | ||||||||||||||||||
84Ga | 31 | 53 | 83.952663(32) | 97.6(12) ms | β− (55%) | 84Ge | 0−# | ||||||||||||
β−, n (43%) | 83Ge | ||||||||||||||||||
β−, 2n (1.6%) | 82Ge | ||||||||||||||||||
85Ga | 31 | 54 | 84.957333(40) | 95.3(10) ms | β−, n (77%) | 84Ge | (5/2−) | ||||||||||||
β− (22%) | 85Ge | ||||||||||||||||||
β−, 2n (1.3%) | 83Ge | ||||||||||||||||||
86Ga | 31 | 55 | 85.96376(43)# | 49(2) ms | β−, n (69%) | 85Ge | |||||||||||||
β−, 2n (16.2%) | 84Ge | ||||||||||||||||||
β− (15%) | 86Ge | ||||||||||||||||||
87Ga | 31 | 56 | 86.96901(54)# | 29(4) ms | β−, n (81%) | 86Ge | 5/2−# | ||||||||||||
β−, 2n (10.2%) | 85Ge | ||||||||||||||||||
β− (9%) | 87Ge | ||||||||||||||||||
88Ga[5] | 31 | 57 | 87.97596(54)# | β−? | 88Ge | ||||||||||||||
β−, n? | 87Ge | ||||||||||||||||||
89Ga[5] | 31 | 58 | |||||||||||||||||
This table header & footer: |
- ^ mGa – Excited nuclear isomer.
- ^ ( ) – Uncertainty (1σ) is given in concise form in parentheses after the corresponding last digits.
- ^ # – Atomic mass marked #: value and uncertainty derived not from purely experimental data, but at least partly from trends from the Mass Surface (TMS).
- ^
Modes of decay:
EC: Electron capture
IT: Isomeric transition n: Neutron emission p: Proton emission - ^ Bold symbol as daughter – Daughter product is stable.
- ^ ( ) spin value – Indicates spin with weak assignment arguments.
- ^ # – Values marked # are not purely derived from experimental data, but at least partly from trends of neighboring nuclides (TNN).
- ^ a b Medical radioisotope used in imaging
- ^ Order of ground state and isomer is uncertain.
Gallium-67
[edit]Gallium-67 (67
Ga), the longest-lived radioactive isotope of gallium with a half-life of 3.2617 days, decays by electron capture with gamma emission to stable zinc-67. It is a radiopharmaceutical used in gallium scans (as is gallium-68). This isotope is imaged by a gamma camera.
It is usually used as the free ion, Ga3+.
Gallium-68
[edit]Gallium-68 (68
Ga) is a positron emitter with a half-life of 67.84 minutes, decaying to stable zinc-68. It is used as a radiopharmaceutical, generated in situ from the electron capture of germanium-68 (half-life 271.05 days) owing to its short half-life. The isotope, where a cyclotron is available, can be made in greater quantities by proton bombardment of 68Zn.[6][7] This positron-emitting isotope can be imaged efficiently by PET scan: see gallium scan. Gallium-68 is normally used as a radioactive label for a ligand which binds to certain tissues, such as DOTATOC and DOTATATE,[8] which are somatostatin analogues useful for imaging neuroendocrine tumors, which gives it a different tissue uptake specificity from the free ion gallium-67 is usually used as. Such scans are useful in locating neuroendocrine tumors and pancreatic cancer.[9] Thus, octreotide scanning for NET tumors (using indium-111) is being increasingly replaced by gallium-68 DOTATOC scan.[10]
See also
[edit]Daughter products other than gallium
References
[edit]- ^ a b c d e Kondev, F. G.; Wang, M.; Huang, W. J.; Naimi, S.; Audi, G. (2021). "The NUBASE2020 evaluation of nuclear properties" (PDF). Chinese Physics C. 45 (3): 030001. doi:10.1088/1674-1137/abddae.
- ^ "Standard Atomic Weights: Gallium". CIAAW. 1987.
- ^ Prohaska, Thomas; Irrgeher, Johanna; Benefield, Jacqueline; Böhlke, John K.; Chesson, Lesley A.; Coplen, Tyler B.; Ding, Tiping; Dunn, Philip J. H.; Gröning, Manfred; Holden, Norman E.; Meijer, Harro A. J. (2022-05-04). "Standard atomic weights of the elements 2021 (IUPAC Technical Report)". Pure and Applied Chemistry. doi:10.1515/pac-2019-0603. ISSN 1365-3075.
- ^ Wang, Meng; Huang, W.J.; Kondev, F.G.; Audi, G.; Naimi, S. (2021). "The AME 2020 atomic mass evaluation (II). Tables, graphs and references*". Chinese Physics C. 45 (3): 030003. doi:10.1088/1674-1137/abddaf.
- ^ a b Shimizu, Y.; Kubo, T.; Sumikama, T.; Fukuda, N.; Takeda, H.; Suzuki, H.; Ahn, D. S.; Inabe, N.; Kusaka, K.; Ohtake, M.; Yanagisawa, Y.; Yoshida, K.; Ichikawa, Y.; Isobe, T.; Otsu, H.; Sato, H.; Sonoda, T.; Murai, D.; Iwasa, N.; Imai, N.; Hirayama, Y.; Jeong, S. C.; Kimura, S.; Miyatake, H.; Mukai, M.; Kim, D. G.; Kim, E.; Yagi, A. (8 April 2024). "Production of new neutron-rich isotopes near the N = 60 isotones Ge 92 and As 93 by in-flight fission of a 345 MeV/nucleon U 238 beam". Physical Review C. 109 (4): 044313. doi:10.1103/PhysRevC.109.044313.
- ^ Kumlin, J; Dam, J; Langkjaer, N; Chua, C.J.; Borjian, S.; Kassaian, A; Hook, B; Zeisler, S; Schaffer, P; Helge, Thisgaard (October 2019). "Multi-Curie Production of Ga-68 on a Biomedical Cyclotron". Conference: EANM'19. Retrieved 13 December 2019.
- ^ Thisgaard, Helge; Kumlin, Joel; Langkjær, Niels; Chua, Jansen; Hook, Brian; Jensen, Mikael; Kassaian, Amir; Zeisler, Stefan; Borjian, Sogol; Cross, Michael; Schaffer, Paul (2021-01-07). "Multi-curie production of gallium-68 on a biomedical cyclotron and automated radiolabelling of PSMA-11 and DOTATATE". EJNMMI Radiopharmacy and Chemistry. 6 (1): 1. doi:10.1186/s41181-020-00114-9. ISSN 2365-421X. PMC 7790954. PMID 33411034.
- ^ Chauhan, Aman; El-Khouli, Riham; Waits, Timothy; Agrawal, Rohitashva; Siddiqui, Fariha; Tarter, Zachary; Horn, Millicent; Weiss, Heidi; Oates, Elizabeth; Evers, B. Mark; Anthony, Lowell (2020-08-11). "Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: A retrospective analysis in neuroendocrine tumor patients". Oncotarget. 11 (32): 3061–3068. doi:10.18632/oncotarget.27695. ISSN 1949-2553. PMC 7429177. PMID 32850010.
- ^ Hofman, M.S.; Kong, G.; Neels, O.C.; Eu, P.; Hong, E.; Hicks, R.J. (2012). "High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours". Journal of Medical Imaging and Radiation Oncology. 56 (1): 40–47. doi:10.1111/j.1754-9485.2011.02327.x. PMID 22339744. S2CID 21843609.
- ^ Scott, A, et al. (2018). "Management of Small Bowel Neuroendocrine Tumors". Journal of Oncology Practice. 14 (8): 471–482. doi:10.1200/JOP.18.00135. PMC 6091496. PMID 30096273.